Driving the next wave of innovation in CAR T-cell therapies

McKinsey insights on cell and gene therapy

Continuing advances in cell and gene therapy (CGT) are transforming how we treat and potentially cure certain diseases. This collection of articles provides an in-depth look at the opportunities and challenges ahead and the implications for stakeholders in this fast-evolving field. Contact us to learn more.

Our insights

Article

A call to action: Opportunities and challenges for CGTs in Europe

– The speed at which scientific breakthroughs in cell and gene therapy translate into advances in European healthcare could depend on how quickly stakeholders address some uniquely European challenges.
Article

Delivering innovation: 2020 oncology market outlook

– At the dawn of a new decade, we take stock of advances and unmet needs in the oncology pharmaceutical market. What will it take to deliver innovation to patients over the next ten years?
Article

Managing China’s growing oncology burden

– Significant increases in incidence rates have made cancer a high priority in China. Progress has resulted from innovative treatments and greater access to care, yet much more needs to be done.
Article

COVID-19 and cell and gene therapy: How to keep innovation on track

– Cell and gene therapies promise life-changing treatments, but the pandemic has hit the sector hard. A survey reveals the extent of the disruption and suggests actions to help companies become more resilient.
Article - McKinsey Global Institute

Ten innovations that can improve global health

– By 2040, new technologies could reduce the total burden of disease by 6 to 10 percent.
Article

Biopharma portfolio strategy in the era of cell and gene therapy

– Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide their portfolio decisions.
Article

Driving the next wave of innovation in CAR T-cell therapies

– Unlocking the full potential of CAR T-cell therapies requires investment in four areas.
Article

Gene therapy coming of age: Opportunities and challenges to getting ahead

– Amid breakthroughs in gene editing, the pharma industry must recalibrate its development and reimbursement model for therapies that go beyond the traditional approach to disease treatment.
Article

An engineering approach to derisking R&D for novel drug modalities

– Borrowing from the field of engineering, applying a “failure modes analysis” can quickly take some unnecessary risk out of a development program for innovative modalities.
Article

Unlocking market access for gene therapies in the United States

– Gene therapy holds great promise for treating a variety of diseases, but without changes, today’s payment system could limit the number of patients who benefit.
Interview

Helping to accelerate cures: Regulating the rapidly evolving field of cell and gene therapies

– In this interview, Peter Marks of the US Food and Drug Administration discusses how the organization has contributed to the broader ecosystem of innovation.